# Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

> **NCT05565092** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Sickle Cell Disease (SCD)

## Interventions

- **DRUG:** ALXN1820

## Key facts

- **NCT ID:** NCT05565092
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-22
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-01-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate program.
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565092, "Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05565092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*